Lineage commitment during embryonic stem cell (ESC) differentiation is controlled not only by a gamut of transcription factors but also by epigenetic events, mainly histone deacetylation and promoter DNA methylation. The DNA demethylation agent 5 0 -aza-2 0 -deoxycytidine (AzadC) has been widely described as an effective promoter of cardiomyogenic differentiation in various stem cell types. However, its toxicity and instability complicate its use. Therefore, the purpose of this study was to examine the effects of zebularine (1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin-2-1), a stable and non-toxic DNA cytosine methylation inhibitor, on mouse ESC (mESC) differentiation. Herein, we report that treating embryoid bodies, generated from mESCs, with 30 lM zebularine for 7 days led to greater cell differentiation and induced the expression of several cardiac-specific markers that were detected using reverse transcription-polymerase chain reaction (RT-PCR), real-time PCR, immunostaining and flow cytometry. Zebularine enhanced the expression of cardiac markers and the appearance of beating cells that responded to cardiac drugs, including ion channel blockers (diltiazem) and b-adrenergic stimulators (isoproterenol). Gene promoter methylation status was assessed using methylation-specific PCR (MSP) and validated by bisulfite sequencing analysis. Global gene expression profiling using microarrays showed that zebularine-differentiated cells are distinct from control ESCs. Pathway analysis revealed an enhancement of cellular processes such as embryonic development, cardiovascular system development and function. In addition, the whole-cell proteins exhibited different profiles as analyzed by two-dimensional differential-in-gel-electrophoresis. Our results indicate that zebularine regulates mesodermal differentiation of mESCs, controls promoter methylation of crucial cardiac genes and may help to improve cardiomyogenic differentiation.
Lineage commitment during embryonic stem cell (ESC) differentiation is controlled not only by a gamut of transcription factors but also by epigenetic events, mainly histone deacetylation and promoter DNA methylation. The DNA demethylation agent 5 0 -aza-2 0 -deoxycytidine (AzadC) has been widely described as an effective promoter of cardiomyogenic differentiation in various stem cell types. However, its toxicity and instability complicate its use. Therefore, the purpose of this study was to examine the effects of zebularine (1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin-2-1), a stable and non-toxic DNA cytosine methylation inhibitor, on mouse ESC (mESC) differentiation. Herein, we report that treating embryoid bodies, generated from mESCs, with 30 lM zebularine for 7 days led to greater cell differentiation and induced the expression of several cardiac-specific markers that were detected using reverse transcription-polymerase chain reaction (RT-PCR), real-time PCR, immunostaining and flow cytometry. Zebularine enhanced the expression of cardiac markers and the appearance of beating cells that responded to cardiac drugs, including ion channel blockers (diltiazem) and b-adrenergic stimulators (isoproterenol). Gene promoter methylation status was assessed using methylation-specific PCR (MSP) and validated by bisulfite sequencing analysis. Global gene expression profiling using microarrays showed that zebularine-differentiated cells are distinct from control ESCs. Pathway analysis revealed an enhancement of cellular processes such as embryonic development, cardiovascular system development and function. In addition, the whole-cell proteins exhibited different profiles as analyzed by two-dimensional differential-in-gel-electrophoresis. Our results indicate that zebularine regulates mesodermal differentiation of mESCs, controls promoter methylation of crucial cardiac genes and may help to improve cardiomyogenic differentiation. Embryonic stem cells (ESCs) hold a great potential for cell replacement, despite a number of significant hurdles that still stand in the way of the realization of that potential. The most important among these are differentiation efficiency, safety concerns and overcoming immune rejection. 1 Currently, ESCs and their resulting differentiated cell types provide a promising in vitro system for the study of early human embryonic development. 2, 3 As such, they can be used as cell lines with genetic disorders 4, 5 and are being used increasingly in drug screening. 6, 7 Differentiation of ESCs requires the repression of transcription factors involved in maintaining pluripotency and the activation of developmental genes. Both processes are directed by specific epigenetic mechanisms. An example of the first process is the promoter-methylation-dependent repression of Nanog and Oct3/4 as cells differentiate. 8 Thus far, the activation of developmental genes during DNAdemethylation-induced stem cell differentiation has been less thoroughly studied. Instead, these developmental genes have been reported as being in a repressed state during the early stages of development because of the establishment of specific patterns of histone modifications, which consist of large regions of H3-Lys27 methylation harbouring smaller regions of H3-Lys4 methylation. 9 This repressive chromatin state is mediated by the Polycomb group of proteins. [10] [11] [12] Besides nitric oxide (NO) 13 many epigenetic compounds efficiently invert genes' methylation status and histone patterns; such compounds are currently in use for the treatment of cancer.
14 Because treatment of ESCs with 5 0 -aza-2 0 -deoxycytidine (AzadC) initiates cardiac differentiation and gene reactivation, 15, 16 we tested the potential effect of zebularine (1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin-2-1) on ESCs.
Zebularine is a cytidine analogue that is able to inhibit DNA methyltransferases (DNMTs) through covalent binding [17] [18] [19] and is a robust inhibitor of cytidine deaminase, a central enzyme for the metabolism of cytosine nucleoside analogues such as AzadC, 20 which is increased in tumour cells as a resistance mechanism to antineoplastic drugs. Zebularine acts during DNA replication, substituting cytosine residues following its phosphorylation and conversion to deoxynucleotide. Once incorporated into DNA, it forms covalent complexes with DNMTs leading to inhibition of its activity, thereby decreasing DNA methylation. 19 Overall, zebularine is a genome-wide demethylating agent with increased activity in proliferative cells.
Unlike AzadC, which is toxic in vitro and in vivo and is unstable in aqueous solution, zebularine is chemically stable in neutral and basic media. 21, 22 In addition, zebularine has a smaller myelosuppressive effect than AzadC; this leads to minimal side effects, making zebularine a candidate drug for long-term tumour treatment by oral administration. 22 We tested the effect of zebularine on mouse ESCs (mESCs) and detected rhythmic and synchronized beating areas in embryoid bodies (EBs). We next studied the gene and protein expression of cardiac markers, finding that zebularine-treated cells highly expressed cardiac-restricted markers and expressed low levels of pluripotency factors. Moreover, when gene expression was compared between cells treated with zebularine, AzadC and NO, the cardiac expression patterns showed that zebularine preferentially drives the differentiation of mESCs towards a cardiomyocyte-like phenotype. These findings support the hypothesis that zebularine regulates mesodermal differentiation more efficiently than the other drugs tested. Next, we analyzed methylation gene promoter status and detected that Nkx2.5, an early marker of the cardiac lineage differentiation program, was clearly unmethylated and thus transcriptionally activated following zebularine treatment. To decipher the global effect of zebularine on gene expression, we performed microarray analysis and found a significant number of differentially expressed genes with a B-statistic 41, demonstrating that the cellular transcriptome is clearly modified following zebularine treatment. The differentially expressed genes were selected using a linear model approach 23 and implemented in the Linear Models for Microarray Bioconductor package and Ingenuity's Pathway Analysis (IPA) software. In addition, experiments having significant signatures or reverse/antisignatures were dissected using the entire mouse gene expression omnibus (GEO) experiments on the mouse Affymetrix platform deposited in the NCBI's GEO database. Moreover, proteins showed different patterns when subjected to two-dimensional differential-in-gel-electrophoresis (2D-DIGE). Finally, we studied the effect of zebularine on human ESCs (hESCs) and observed differences in the expression levels of some cardiac-specific genes after treatment.
Results
Zebularine preferably drives mESCs towards mesodermal lineage. On the basis of the previous results demonstrating that AzadC and NO were able to promote cardiac differentiation of ESCs, we tested and compared the effect of zebularine on mESCs in standard culture conditions ( þ LIF (leukemia inhibitory factor)). Using reverse transcription-polymerase chain reaction (RT-PCR), we compared gene expression after treatment with each of these three molecules. When AzadC or NO was used, we observed that pluripotency markers were expressed at levels similar to control samples, whereas cardiac-specific genes were slightly increased. The expression of Gata4, Actc, Myh6, Myh7, cTnT and Anf was higher in AzadC-and NO-treated cells than in control cells. In contrast, Serca2 was expressed similarly in all samples. The only difference detected was the expression of cTnI in NO addition and Hprt in AzadC treatment. Interestingly, when we compared gene expression in zebularine-, AzadC-and NO-treated cells, we observed that zebularine caused a reduction in the expression of the pluripotency markers Oct3/4, Nanog and FoxD3 than did AzadC or NO. Moreover, zebularinetreated cells demonstrated higher expression of genes, especially those expressed in cardiac tissues, such as Actc, Anf, cTnT, cTnI, Myh6 and Myh7. Serca2 was expressed at a level similar to the other samples ( Figure 1a) .
As widely known, EB-mediated differentiation is the most common method to induce spontaneous cardiac differentiation; however, the results of this differentiation have been fairly successful. Athough we postulated that zebularine could be considered a critical parameter for optimizing early in vitro mesodermal differentiation, we treated EBs with 30 mM of zebularine, and then we assessed the gene expression at differentiating days 3, 5 and 7 for the three associated lineage markers (Figure 1b) . We found that markers from different lineages are detected, interestingly, in zebularine-treated EBs, mesoderm markers (Brachyury, Gata4, Nkx2.5, aSMA, Desmin, Flk1, Hrt1, Mef2c BMP2, BMP4 and Noggin), which are markedly expressed starting at day 5; however, SM22a and Serca2 are equally detected in all experimental conditions. Moreover both endoderm markers (Sox17, Pdx1, FoxA2, Sox7, Pax4, P48, Mist and Nkx6.1) and ectoderm markers (Wt1, Snail1, Slug, Otx2, Zic1, Nestin, Ngn, Pax6, Isl1 and Sox1) are less or not detected at differentiating days 3, 5 and 7 when compared with control EBs, and in addition, Oct4 and Nanog are slightly less detected in zebularine-treated EBs compared with control and ( À LIF). These results imply that zebularine is more efficient than AzadC or NO at promoting mesodermal gene expression.
Because of its lower toxicity, zebularine could potentially be used as a substitute for AzadC. To validate this hypothesis, we measured and compared Annexin-V incorporation at differentiating days 3, 5 and 7 ( Figure 1c ) and found that apoptosis was significantly reduced in zebularine compared with AzadC, and even more at day 3, where significant increase of apoptosis occurs as for AzadC, thus confirming that zebularine has no cytotoxic effect on EBs.
Zebularine promotes the expression of cardiac-specific genes and proteins. We used real-time PCR to analyze the mRNA levels of genes related to cardiac differentiation, and genes involved in the functional machinery of cardiac cells in EBs leaved to spontaneous differentiation during 7 days (from now on defined as Control) and EBs treated with zebularine (from now on defined as Zebularine) (Figure 2a) . We detected elevated mRNA levels of cardiac-precursor genes Nkx2.5 (enhanced 1.8-fold (P40.05)) and Gata4 (enhanced 2.6-fold (P40.05)), both essential for cardiac cell commitment, elevated the expression of genes whose encoded proteins are essential components of contractile cardiac machinery, such as Actc, cTnI, cTnT, Myh7, Myl7 and Myl2, and increased the expression of other genes essential for cardiac development and function, such as Anf, Flk1, Hrt1 and Mef2c (Figure 2b ).
Using western blotting (Figure 2c ), we found that zebularine promotes the expression of proteins that are restricted to mesoderm and cardiac phenotypes, such as Gata4, Actc, Myh7, cTnt, Anf, Desmin, Flk1 and a-actin. Immunostaining analysis (Figure 2d) showed that the precursor Gata4 was expressed at higher levels in zebularine-treated EBs and had Time course of zebularine treatment on lineage formation: mESCs cells were cultured as hanging drop during 3 days to form EBs and differentiate to derivatives of the three germ layers and then leaved in culture without treatment (Control) or treated with 30 mM zebularine. Gene expression was assessed in parallel at differentiating days 3, 5 and 7. Cells cultured without LIF ( À LIF) are used as negative control for lineage formation. RT-PCR was performed with primers to detect pluripotency markers (Oct3/4 and Nanog), endoderm-specific markers (Sox17, Pdx1, FoxA2, Pax4, P48, Mist and Nkx6.1), mesoderm-specific markers (Brachyury, Gata4, Nkx2.5, aSMA, SM22a, Desmin, Flk1, Hrt1, Mef2c, tbx5, BMP2, BMP4, Serca2 and Noggin) and ectoderm-specific markers (Wt1, Snail1, Slug, Otx2, Zic1, Nestin, Ngn, Pax6. Islet1 and Sox1). b-Actin was used as the input control. a primarily nuclear distribution, whereas no expression was detected in control cells. Moreover, Actc and Myh7 proteins were markedly increased in cells treated with zebularine. Actc was clearly distributed in the cellular cytoskeleton and cellular prolongations in comparison to control cells, which only expressed low levels of this protein. Myh7 demonstrated a similar cytoskeletal distribution in treated cells and was not detected in control. Anf was expressed after zebularine treatment but not in control cells. Furthermore, Flk1 and Desmin, two proteins involved in cardiovascular system development, had increased expression following zebularine treatment (Figure 2d) . Finally, by flow cytometry analysis we detected that cells treated with zebularine were more positive to proteins involved in cardiac differentiation and functionality (Figure 2e ). Zebularine-treated cells are 15.17% more positive to Gata4, 10.53% to Actc, 4.29% to Flk1, 7.99% to Myh7, 5.18% to sarcomeric-Actc, 8.83% to Anf and 4.09% to Desmin. These results suggest that zebularine is able to induce the expression of cardiac-specific genes and proteins.
The beating areas resulting from zebularine treatment respond to chronotropic drugs. Zebularine treatment resulted in the appearance of beating areas that showed rhythmic and coordinated contractions (Supplementary Movie 1). To determine whether these contractions were functional, we used cardiotropic drugs to alter beating frequency. We administrated isoproterenol, which acts on b-adrenergic receptors, and diltiazem, a calcium channel blocker that produces a decrease in cardiac rhythm, provoking negative ionotropic and chronotropic function. After the addition of 2 mM isoproterenol (Figure 3a ), we observed a 135.00% enhancement in contraction frequency after 1 min and a 126.25% enhancement after 2 min of exposure, demonstrating that isoproterenol provokes a very Zebularine modifies the promoter methylation state of Nkx2.5. To determine whether zebularine produces changes in the methylation patterns, we studied gene promoter methylation status using methylation-specific PCR (MSP).
As Figure 4a depicts, the pluripotency markers Oct3/4 and Nanog were transcriptionally active in control samples (unmethylated). This contrasts with zebularine-treated EBs, which had methylated promoters, suggesting that zebularine induced methylation-based gene silencing. In contrast, the Sox2 promoter was unmethylated in both samples, indicating that Sox2 expression was unaffected by zebularine. Moreover, the promoters of Gata4 and Serca2 were in an unmethylated state in both control and treated cells, suggesting that the expression of these genes was unaffected by zebularine. Interestingly, Nkx2.5 was epigenetically repressed in control cells, but appeared unmethylated in zebularinetreated cells. As Nkx2.5 associates with members of the GATA family, activates cardiac structural genes and is essential to initiate the cardiac differentiation, these data indicate that zebularine was able to induce demethylation of Nkx2.5, which leads to its expression, thereby promoting the expression of other fundamental genes during the cardiac differentiation of ESCs.
To confirm and validate the promoter methylation status of Nkx2.5 and Gata4, bisulfite-treated genomic DNAs obtained from Control, zebularine and AzadC samples were amplified, Figure 4b , we found that the methylation pattern did not change and the Gata4 promoter remains completely unmethylated, however; and in concordance with the MSP results, Nkx2.5 promoter was almost completely unmethylated for zebularine and predominately methylated for AzadC (Figure 4c) .
Consequently, we analyzed the activity of DNA demethylases and DNMTs. Following zebularine addition, DNA demethylase activity was significantly enhanced by 129.01% (Po0.01), whereas DNMT activity was reduced 14.20% (P ¼ 0.01) compared with control cells (Figure 5a ). These data suggest that promoter methylation is reduced when cells are treated with zebularine and subsequently zebularine acts on DNMTs, decreasing their activity.
We also studied histone methyltransferase (HMT) activity for histone H3 lysine 9 (H3K9) and histone H3 lysine 4 (H3K4). After zebularine treatment, we found a 60.77% (P ¼ 0.017) reduction of HMT activity at H3K9, which is considered a marker for heterochromatin. In addition, the HMT activity at H3K4, a hallmark of euchromatin, was increased by 32.8% (P ¼ 0.01) after zebularine treatment (Figure 5b ). We also detected that histone deacetylase (HDAC) activity was reduced by 52.74% (P ¼ 0.017) compared with control samples, indicating that chromatin exists in a more relaxed (Figure 5c ). Although zebularine enhanced histone H4 acetylation, the acetylation state of histones plays a central role in determining gene expression and its overexpression could indicate a transcriptional upregulation; H3K4 and H3K9 methylation are detectable in zebularine-treated cells, the level of H3K9 methylation appears no different compared with control and H3K4 methylation appears slightly increased (Figure 5d ), indicating the establishment of a specific pattern of histone modification.
These data indicate that zebularine acts as a chromatinmodifying agent, inducing methylation and silencing of Oct3/4 and Nanog, both of which are essential to maintain pluripotency. In addition, this drug is able to demethylate and increase the expression of Nkx2.5, which directs cells to enter a cardiomyocyte differentiation program. Moreover, zebularine indirectly alters the activity of enzymes that are implicated in the epigenetic regulation of gene transcription and chromatin structure.
Zebularine alters global gene expression profiling. To characterize the genome-wide gene expression profile, we used Affymetrix microarray platform. A set of differentially expressed genes is presented as a heatmap to illustrate groups of coregulated genes; hierarchical clustering ( Figure 6a ) indicated that the gene expression profile of zebularine is distinct from that of control. The data were then globally normalized, filtered and deposited in NCBI's GEO database (GSE29072). Using Gene Ontology categories, 266 genes (119 upregulated and 147 downregulated) were identified from a total of 45 102 genes as having an expression level that differed significantly (Po0.001) upon zebularine treatment. The potential functions and known biological roles of these genes are listed in Supplementary  Table 2 . Data were most associated with biological process, system development, organ and multiorgan development, anatomical structure development, anatomical structure morphogenesis, cellular components and molecular functions. Some of the genes upregulated by zebularine matched the mesoderm markers, these include BMP4 and Brachyury.
We compared our microarray results with the results from other studies by analyzing all mouse GEO studies that used the mouse Affymetrix platform in the GEO database. A high positive score implies that the mouse GEO studies shares over-and underexpressed signatures with our experiment, whereas a high negative score indicates a reverse or antipattern compared with our study. The scores were These computations were carried out using the GEO query package of R Bioconductor and the statistical packages in R.
Out of the microarrays we analyzed, 3750 showed a significantly similar or significantly reverse signature to our experiment; as a first approximation, we focused on similarity/ dissimilarity scores with a Po0.05 and found 71 studies with high similarity to our results (P-values from 0.695 to 1) and 54 studies with low similarity (P-values from À 0.695 to À 1) ( Table 1) . As this classification is very approximate and gives only basic information, we also analyzed the data using IPA to classify specific groups of genes involved in cellular functions related to cardiogenesis (Figure 6b) . Interestingly, the most often recorded biological functions were related to skeletal, muscular and cardiovascular system development and function, tissue development, cell-to-cell signaling and embryonic development. In addition to these gene expression changes, 2D-DIGE proteomics assay results showed that zebularine also affects protein mobility patterns, altering the acidic shift in several proteins (Figure 6c) .
Zebularine enhances the expression of cardiac lineage markers in hESCs. We speculated whether zebularine was able to produce the same effect on hESCs. To address this issue, we used HS-181 -an hESC cell line. After 7 days of treatment, no beating areas were detected. To determine whether zebularine-treated hESCs possessed cardiac expression markers, we analyzed the gene expression using RT-PCR (Figure 7a) . As with mESCs, we detected Gata4 expression in control and treated samples, and increased expression of Actc, Myh7, Myh6, cTnI, Serca2 and Anf in zebularine-differentiated cells; however, no expression of Myl2 and Myl7 was detected, possibly explaining the absence of contractile areas in treated cells. We then studied the protein expression using immunostaining (Figure 7b ) and detected that zebularine slightly enhanced the protein levels of Gata4, Myh7, Actc and Anf. In addition, results from an hESC-specific protein array demonstrated a slight inhibition of pluripotency marker expression and increased levels of mesodermic proteins after zebularine treatment (Figures 7c  and d) . As a result, zebularine is able to induce cardiacspecific gene and protein expression in HS-181, although less effectively than in mESCs. Future comparative investigations will shed light on whether zebularine is able to induce complete cardiac differentiation in various cell types.
Discussion
It has been widely demonstrated that ESCs are able to give rise to cardiomyocytes when treated with growth factors and chemical compounds. [25] [26] [27] [28] Among the many different protocols used to differentiate ESCs towards cardiomyocytes, NO addition to ESC culture was able to upregulate cardiomyogenesis processes and inhibit cell death. [29] [30] [31] AzadC has also been demonstrated to be an activator of the cardiac differentiation, 15 although 1 mM of AzadC leads to cell death and disappearance of the cardiac phenotype. Thus, AzadC possesses a significant limitation in producing cardiac-like cells from ESCs because of its cytotoxicity and inability to maintain a cardiac phenotype.
In this study, we demonstrated that zebularine is able to induce a mesodermal differentiation in mESCs and found that its application led to the increased expression of cardiacrestricted genes. Beyond the overexpression of cardiomyocyte-specific markers, we found that the pluripotency markers were downregulated. Interestingly, based on gene expression, zebularine appears to be more efficient at promoting the development of cardiac phenotypes than AzadC and NO, particularly in light of some reports suggesting that AzadC fails to differentiate stem cells to a cardiac lineage. 32, 33 Furthermore, protein expression analysis confirmed that proteins involved in cardiac differentiation and functionality were highly expressed in the treated cells. These data were supported by immunostaining and flow cytometry analysis. To Bold text denotes studies that involve the use of different agents (AzadC, Retinoic Acid, DMSO) for ESC differentiation, cardiac development and DNA demethylation, and the GEO accession number for these studies are in italics within parentheses. 
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Mesodermal differentiation by zebularine A Horrillo et al our knowledge, this is the first time that zebularine has been shown to differentiate ESCs towards cardiac-like cells more efficiently than other tested drugs. Also, we observed that zebularine addition induced rhythmic and coordinated contractions and the ability to respond to cardiotropic drugs, suggesting that zebularinetreated cells possess cardiac-like functionality.
During cell differentiation, it has been suggested that the accumulation of cell lineage-specific methylation patterns could give rise to tissue-dependent and differentially methylated regions, such as those found in some CpG islands. 34 This indicates that promoter methylation of specific genes involved in cellular differentiation may occur and thereby commit cells towards a specific lineage. Analysis of promoter methylation status of some genes involved in pluripotency and cellular differentiation showed that after zebularine administration, Oct3/4 and Nanog were transcriptionally inactivated via DNA methylation, suggesting that these cells would be biased towards differentiation. Meanwhile, the Nkx2.5 gene was clearly more activated after zebularine treatment, as its promoter became unmethylated. This indicates that cells treated with zebularine not only decrease the expression of pluripotency markers but also start to express genes that have pivotal roles in cardiac differentiation. In addition, we have demonstrated that zebularine is able to enhance histone H4 acetylation and modify the activity of HDAC and DNMT, in addition to reducing the methylation of H3K9. Zebularine also enhanced DNA demethylase activity and increased the methylation of H3K4. Hence, these global modifications induced by zebularine open and relax the structure of chromatin, increasing the accessibility of promoters to transcriptional machinery.
It has been recently suggested that DNMTs, in addition to incorporating methyl groups into gene promoter regions, may also enforce gene silencing through the recruitment of transcriptional repressor protein complexes that carry proteins with HDAC activity. 35 This would create a scenario where DNA methylation is correlated with the compaction of chromatin structure. This suggestion is in concordance with our data that demonstrate a decrease of DNMT activity in conjunction with a decrease in HDAC activity.
Furthermore, using genome-wide expression array and 2D-DIGE protein analyses, we have demonstrated that zebularine strongly modifies gene and protein expression. Interestingly, our microarray data matched existing GEO studies (with a high similarity score). However, further analyses should be performed, at least at the protein level.
Finally, zebularine treatment of hESCs enhanced cardiacrestricted genes and protein expression, although no beating cells were detected. The absence of beating areas could be explained by the fact that zebularine is incorporated into DNA during the S phase of the cell cycle. As the doubling time of hESCs is longer than that of mESCs, this would explain why zebularine was less efficient in hESCs than in mESCs. Moreover, a protein array panel demonstrated a quantitative increase in mesoderm markers and a slight decrease in pluripotency markers.
These results provide new mechanistic insights regarding the function of zebularine during early ESC differentiation. The link between zebularine and its epigenetic effects opens a new field of investigation aimed at defining the rules of differentiation processes. Indeed, the possibility of priming normal cells with zebularine ex vivo may represent a strategy to obtain specialized cell populations potentially useful for cell therapy.
Materials and Methods
Cell culture and drug administration. The mouse ESC cell line (ES-D3 (D3); ATCC Number: CRL-1934) was cultured in DMEM (Dulbecco's medium) with 15% FBS, 10 U/ml penicillin, 10 mg/ml streptomycin, 2 mM glutamine, 10 À 4 M bmercaptoethanol, 1 Â non-essential amino acids and 10 3 U/ml LIF, and then maintained at 37 1C and 5% CO 2 . The drug administration to mESCs was prepared in three different experimental ways: (1) standard culture conditions in presence of LIF to compare the effect of different agents: the cells were divided into control group, NO-treated group, Azad-C-treated group and zebularine-treated group, control cultures ( þ LIF) were left untreated and experimental cultures were treated with 1 mg/ml AzadC, 100 mM of NO and 30 mM of zebularine for 7 days. (2) In vitro differentiation to generate derivatives of the three primary germ layers: EBs were generated using the hanging drop method during 3 days in the absence of LIF, and then plated and incubated for 24 h in a 10-cm plastic dish in DMEM medium without LIF to adhere, control cultures were left untreated and experimental cultures were treated with 30 mM of zebularine for 3, 5 and 7 days; in parallel cells cultured in monolayer without LIF and without generating EBs, ( À LIF) were used as negative control. (3) Effect of zebularine on mESC differentiation: EBs were generated as in experimental point 2 and the cells were treated with 30 mM of zebularine for 7 days (see Figure 2a) .
The human ESC cell line (HS-181) was derived in the Fertility Unit of Karolinska University Hospital, Huddinge at the Karolinska Institute after approval of a project entitled 'Derivation and early differentiation and characterization of hESC lines' by the Karolinska Institute Research Ethics Board South, Drno 454/02. This line was derived from an embryo that could not be used for the infertility treatment of a couple. Both partners of the couple signed a consent form for donation of the embryo for derivation of a possible permanent stem cell line to be used in stem cell research. The HS-181 line is included in the EU hESC registry (http:// www.hescreg.eu/) and cultured as described by Hovatta et al. 36 To promote differentiation, cells were cultured on Matrigel, bFGF was withdrawn from the medium and cells were subjected to EB formation and 30 mM zebularine treatment for 7 days, as described for mESCs.
Analysis of apoptosis. Apoptosis was evaluated using an Annexin-V-FITC apoptosis detection kit II (BD Pharmingen, San Diego, CA, USA). Briefly, the cells were divided into Control group, zebularine-treated group and Azad-C-treated group. In each time point (3, 5 and 7 days), cells were trypsinized to prepare a single-cell suspension (detached cells) and centrifuged at 1800 r/min for 6 min at 4 1C. Cell pellets were washed two times with cold PBS and then stained with Annexin-V-FITC and propidium iodide (PI), following the manufacturer's instructions. For each sample, FITC-Annexin-V and PI staining were analyzed using Flow Cytometry (BD FACSCalibur cytometry System, San Jose, CA, USA). The data were analyzed using the CellQuest software (BD, San Jose, CA, USA).
Control samples were normalized to 1. The SPSS statistical package (v. 13.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data were analyzed for statistical significance using one-way ANOVA and Tukey's B test: an analysis of variance type I (ANOVA I) was used to determine the statistical significance differences between treatments. Once confirmed, Tukey's B discriminatory analysis was performed to determine the existence of significance differences between the groups.
Flow cytometry. Cardiac proteins expression was analyzed by flow cytometry. Briefly, EBs were trypsinized and fixed with 4% paraformaldehyde. The cells were treated with blocking solution (PBS containing 3% BSA, 0.1% Triton X-100), and incubated for 1 h at 4 1C with primary anti-Gata4, anti-Actc, antiFlk1, anti-Myh7, anti-sarcomeric Actc, anti-Anf and anti-Desmin. After washing, the cells were incubated for 30 min with secondary antibodies. Unlabeled cells and cells labeled with secondary antibody were used as controls. The data were analyzed using the CellQuest software to calculate the percentage of positive cells.
RT-PCR analysis. Total RNA was extracted from control and treated cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. RNA concentration was quantified using a NanoDrop spectrophotometer, and 1 mg of total RNA was reverse transcribed using MMLV retrotranscriptase (Promega, Madison, WI, USA) and random hexamers.
cDNA was amplified using 0.05 U/ml of Eco-Taq polymerase (Ecogen, Barcelona, Spain) and 400 nM of specific primers. In all, 26 amplification cycles were used. Quantitative real-time PCR was performed using SYBR-Green and detected using an ABI Prism 7500 system (Applied Biosystems, Foster City, CA, USA). Primer information is described in Supplementary Table 1 .
Western blotting assay. Cells were lysed in RIPA buffer (Sigma-Aldrich, St Louis, MO, USA) complete with protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Protein concentration was quantified by Bradford colorimetric assay (Sigma-Aldrich), and 20 mg of proteins were separated using SDS-PAGE, transferred to PDVF membrane and probed with anti-b-actin (Sigma-Aldrich; A5441), anti-Actc (Santa Cruz Biotechnology, Dallas, TX, USA; SC15335), anti-Gata4 (Abcam, Cambridge, UK; AB4132), anti-Myh7 (Santa Cruz Biotechnology; SC12117), anti-Anf (Abcam; AB5490), anti-cTnT (Abcam; AB10214), anti-Desmin (Sigma-Aldrich; D8281), anti-Flk1 (Millipore, Billerica, MA, USA; 07-716), anti-sarcomeric Actc (Sigma-Aldrich; A7811), anti-acetyl histone H4 (Upstate, Lake Placid, NY, USA; 06-598), antimonomethyl Lys9 H3 (Upstate; 07-450) and anti-trimethyl Lys4 H3 (Upstate; 07-473).
Immunofluorescence staining. Cells were fixed and permeabilized with methanol, incubated at À 20 1C for 20 min and blocked with donkey serum in PBS (pH 7.4), and then labeled with appropriate primary antibodies (1:1000). The primary antibodies used were mostly the same as those used for western blotting, and the secondary antibodies used were Alexa Fluor 488 goat anti-rabbit (Invitrogen; A11034), Alexa Fluor 488 goat anti-mouse (Invitrogen; A11029) and Alexa Fluor 568 donkey anti-goat (Invitrogen; A11057). Digital images were obtained using a Leica SP5 confocal microscope (Leica, Mannheim, Germany) or an Olympus IX71 inverted microscope (Olympus, Tokyo, Japan).
Proteome profile array. Protein expression profiles were assayed using the specific human pluripotent Stem Cell array kit 'Proteome Profiler Array' (R&D Systems Europe, Abingdon, UK; ARY010) following the manufacturer's instructions. This array allowed us to detect simultaneously 15 different stem cell markers related to pluripotency and differentiation processes. The densitometry analysis of the resulting spots was carried out using the ImageJ 1.41 software (Wayne Rasband, NIH, Bethesda, MD, USA).
Chronotropic drugs treatment. Beating areas of cell culture treated with zebularine were subjected to 2 mM isoproterenol, and the frequency of beating was counted 1 and 2 min after treatment. The medium was changed and 50 mM diltiazem was added to the cultures, and contractions were counted until they stopped. Movies were captured on Olympus IX71 inverted microscope using Olympus DP70 digital camera system (Olympus) and the Olympus DP Controller software (Olympus).
Bisulfite modification and MSP. Genomic DNA was extracted by phenol-chloroform extraction and purified using the Wizard DNA Clean-up system (Promega). Bisulfite modification was performed using the EZ-DNA Methylationgold kit (Zymo Research Corp., Irvine, CA, USA) following the manufacturer's instructions. Specific primers (Supplementary Table 1) were designed using Methyl Primer Express Software (Applied Biosystems), and MSP was performed as follows: 95 1C for 3 min, 40 cycles of 95 1C for 30 s, 55 1C for 1 min, 72 1C for 1 min and 72 1C for 7 min. Samples were loaded on a 2% agarose gel.
Bisulfite sequencing. DNA was isolated using DNeasy kit (Qiagen, Hilden, Germany) from EBs (Control, Zebularine and Azad-C) grown for 7 days to allow differentiation. In all, 1 mg of DNA was then bisulphite converted using the Cells-toCpG M Bisulfite Conversion kit (Applied Biosystems) according to the manufacturer's recommendation. Methyl Primer Express Software (Applied Biosystems) was used to design primers for CpG islands flanking the same sequence region used for MSP (Supplementary Table 1 ). Bisulfite-modified DNA was amplified using a hot start Taq polymerase (MyTaq HS Red DNA Polymerase; Bioline Reagents Ltd., London, UK), starting with denaturation at 95 1C for 5 min, and then 35 cycles of denaturation at 95 1C for 30 s, annealing at optimal T m for 15 s, extension at 72 1C for 15 s, followed by an extra extension at 72 1C for 10 min. Amplicons were purified using the QIAquick PCR Purification kit (Qiagen) and were cloned in pGEM-T vector at a 3:1 insert:vector molar ratio. DH5a-competent cells (Invitrogen) were transformed by heat shock and grown overnight on LB-agar plates containing ampicillin, X-gal and IPTG. CpG primers described above was used to amplify bisulfite-modified DNA directly from 4 to 10 white colonies; amplicons were then purified enzymatically with ExoSAP-IT (USB, Cleveland, OH, USA) and 50 ng of PCR product were bidirectionally sequenced using the BigDye Terminator v.3.1 Cycle Sequencing kit (Applied Biosystems). Fragments were separated on an ABI3730xl DNA Analyzer (Applied Biosystems) and analyzed with Variant Reporter Software v.1.0 (Applied Biosystems). BiQ Analyzer software (Max-Planck-Institut, Saarbrüken, Germany) was used to analyze methylation patterns and generate diagrams. In all, 1 mg of DNA from Control EBs was methylated by MSssI CpG methyltransferase using the recommended protocol (New England Biolabs, Ipswich, MA, USA) and used in parallel with samples as control for bisulfite conversion and sequencing efficiency and accuracy.
Epigenetic enzyme activity analysis. The epigenetic enzyme activity measurements and calculations were performed according to the manufacturer's protocols and formulas. DNMTs activity (Catalog no.: P-3001), HMT activity H3K4 (Catalog no.: P-3002), HMT activity H3K9 (Catalog no.: P-3003) and demethylase activity (Catalog no.: P-3019) were measured using 10 mg of nuclear protein extracts in the EpiQuik Kits (Epigentek, Farmingdale, NY, USA). HDAC activity was analyzed using the HDAC Colorimetric Assay Kit (BioVision, Milpitas, CA, USA), and the colorimetric intensity was measured using a Varioskan Flash microplate reader (Thermo Electron, Vantaa, Finland). Nuclear proteins were isolated using the Subcellular Proteome Extraction Kit (Calbiochem, San Diego, USA), and 5 mg of extracts were used for this assay.
Microarray analysis. Total RNA was isolated using the RNeasy Mini Kit (Qiagen), and 1 mg was used to obtain the gene expression profile of each sample. The signals were quantified using spectrophotometry and verified using a microfluidics-based platform (Genomic core facility of CABIMER). All samples showed the characteristics of high-quality RNA and were subjected to subsequent analysis. cRNA was hybridized on an Affymetrix GeneChip Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA, USA). The data presented in this publication have been deposited in NCBI's GEO 37 and are accessible through GEO Series accession number GSE29072 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29072). In addition, data were subjected to Gene Ontology analysis and IPA software to determine the possible biological functions and pathways.
